Medtronic reported its Q2 fiscal year 2026 results (ended in October):
Revenue: +6.6% YoY — exceeding market expectations.
EPS: +7.9% YoY — also beating forecasts.
Cardiovascular segment: Grew by 10.8%.
Growth Drivers:
Technological Breakthroughs:
Affera & Sphere-9: The cardiac mapping system’s install base doubled during the quarter.
Symplicity Spyral: This hypertension treatment device has received approval from major US insurers (covering 30 million lives). The potential market is estimated at 18 million patients in the US alone.
Strategic Moves:
Within this calendar year, Medtronic is spinning off its diabetes division into a separate company, MiniMed. This is expected to unlock hidden value for shareholders and allow the core business to focus on higher-margin products.
On February 3, 2026, Medtronic announced its intention to acquire CathWorks for $585 million. The deal provides access to the FFRangio system, a non-invasive technology for diagnosing coronary artery disease, further strengthening a cardiology portfolio that accounts for nearly 40% of total revenue.
Dividends:
The company has raised its dividend for 47 consecutive years. The 48th increase is expected in just a few months.
Dividend yield: ~2.8%
Technical Analysis:
The stock is currently trading within an ascending channel.
The price has broken through a local resistance level and successfully completed a retest.
Revenue: +6.6% YoY — exceeding market expectations.
EPS: +7.9% YoY — also beating forecasts.
Cardiovascular segment: Grew by 10.8%.
Growth Drivers:
Technological Breakthroughs:
Affera & Sphere-9: The cardiac mapping system’s install base doubled during the quarter.
Symplicity Spyral: This hypertension treatment device has received approval from major US insurers (covering 30 million lives). The potential market is estimated at 18 million patients in the US alone.
Strategic Moves:
Within this calendar year, Medtronic is spinning off its diabetes division into a separate company, MiniMed. This is expected to unlock hidden value for shareholders and allow the core business to focus on higher-margin products.
On February 3, 2026, Medtronic announced its intention to acquire CathWorks for $585 million. The deal provides access to the FFRangio system, a non-invasive technology for diagnosing coronary artery disease, further strengthening a cardiology portfolio that accounts for nearly 40% of total revenue.
Dividends:
The company has raised its dividend for 47 consecutive years. The 48th increase is expected in just a few months.
Dividend yield: ~2.8%
Technical Analysis:
The stock is currently trading within an ascending channel.
The price has broken through a local resistance level and successfully completed a retest.
Aviso legal
As informações e publicações não se destinam a ser, e não constituem, conselhos ou recomendações financeiras, de investimento, comerciais ou de outro tipo fornecidos ou endossados pela TradingView. Leia mais nos Termos de Uso.
Aviso legal
As informações e publicações não se destinam a ser, e não constituem, conselhos ou recomendações financeiras, de investimento, comerciais ou de outro tipo fornecidos ou endossados pela TradingView. Leia mais nos Termos de Uso.